Mirum Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report5 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Mirum Pharmaceuticals, Inc.
84.74
−11.04%
vs ±9.3% implied · ×1.19
shaded = implied · ▲▼ = realized
Mirum Pharmaceuticals has 12 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceThrough the Shire License Agreement, we were assigned the rights to the license agreement ("Pfizer Agreement"), with Pfizer Inc. ("Pfizer"), pursuant to which we obtained an exclusive, worldwide license to Pfizer's know-how related to Livmarli, (the "Pfizer Know-How").
SentenceThrough the Shire License Agreement, we were assigned the rights to the license agreement, as amended ("Sanofi Agreement"), with Sanofi-Aventis Deutschland GmbH ("Sanofi"), under which we obtained an exclusive, worldwide license to certain patents and know-how controlled by Sanofi related to volixibat ("Sanofi Technology").
SentenceThrough the Bile Acid Portfolio Acquisition, we were assigned the rights to the Asset Purchase Agreement ("Asklepion APA"), dated January 10, 2015, between Travere and Asklepion Pharmaceuticals, LLC ("Asklepion"), pursuant to which we acquired all right, title and interest to certain assets of Asklepion aimed at the development of products related to cholic acid ("Cholic Acid Products").
MIRM 10-Kaccession 0001759425-26-000013
SentenceOn January 23, 2026, we completed the acquisition (the "Bluejay Acquisition") of Bluejay Therapeutics, Inc. ("Bluejay") and its lead product candidate brelovitug (BJT-778).
MIRM 10-Kaccession 0001759425-26-000013
SentenceIn October 2024, we completed a license agreement with Enthorin Therapeutics, LLC and Dart Neuroscience LLC granting us the worldwide right to develop and commercialize MRM-3379, an allosteric inhibitor of Phosphodiesterase 4D ("PDE4D").
MIRM 10-Kaccession 0001759425-26-000013
SentenceIn October 2024, we completed a license agreement with Enthorin Therapeutics, LLC and Dart Neuroscience LLC granting us the worldwide right to develop and commercialize MRM-3379, an allosteric inhibitor of Phosphodiesterase 4D ("PDE4D").
MIRM 10-Kaccession 0001759425-26-000013
SentenceOn October 22, 2024, we entered into a license agreement (the "MRM-3379 License") with Enthorin Therapeutics, LLC and Dart Neuroscience LLC (collectively "Enthorin").
MIRM 10-Kaccession 0001759425-26-000013
SentenceWe acquired licensed rights to develop brelovitug from Novartis, and the manufacture of brelovitug depends on a cell-line license from Lonza.
MIRM 10-Kaccession 0001759425-26-000013
SentenceWe acquired licensed rights to develop brelovitug from Novartis, and the manufacture of brelovitug depends on a cell-line license from Lonza.
MIRM 10-Kaccession 0001759425-26-000013
SentenceUnder the Shire License Agreement, the Asset Purchase Agreement with Travere, license agreement with Enthorin Therapeutics, LLC ("Enthorin"), Bluejay's license agreement with Novartis Pharma AG, which we acquired as part of the Bluejay Acquisition in January 2026 (see below), as well as our other license and acquisition agreements, we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under those agreements.
MIRM 10-Kaccession 0001759425-26-000013
SentenceFor example, we entered into an assignment and license agreement with Shire pursuant to which we were assigned exclusive global rights to license intellectual property and know-how related to Livmarli and volixibat, rights to license know-how related to Livmarli from Pfizer, certain patents and know-how related to volixibat from Sanofi and certain patents and know-how related to Livmarli and volixibat from Satiogen, which we subsequently acquired in May 2022.
MIRM 10-Kaccession 0001759425-26-000013
SentenceFor example, we entered into an assignment and license agreement with Shire pursuant to which we were assigned exclusive global rights to license intellectual property and know-how related to Livmarli and volixibat, rights to license know-how related to Livmarli from Pfizer, certain patents and know-how related to volixibat from Sanofi and certain patents and know-how related to Livmarli and volixibat from Satiogen, which we subsequently acquired in May 2022.
MIRM 10-Kaccession 0001759425-26-000013
SentenceOur approved medicines are currently distributed in the U.S. and Canada, through a single specialty pharmacy in each country.
MIRM 10-Kaccession 0001759425-26-000013
Sentence
Under our license agreement with Takeda as well as agreements with distributors, we may receive large periodic orders for our products.
MIRM 10-Kaccession 0001759425-26-000013
Linked news
Expected move
No implied move.